{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T11:46:17Z","timestamp":1769946377631,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,7,25]],"date-time":"2014-07-25T00:00:00Z","timestamp":1406246400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s00280-014-2521-x","type":"journal-article","created":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T07:24:11Z","timestamp":1406186651000},"page":"629-636","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors"],"prefix":"10.1007","volume":"74","author":[{"given":"Toshihiko","family":"Doi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Onozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomu","family":"Fuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail","family":"Akimov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Robson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,25]]},"reference":[{"key":"2521_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-08-0132","volume":"15","author":"U Banerji","year":"2009","unstructured":"Banerji U (2009) Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15:9\u201314","journal-title":"Clin Cancer Res"},{"key":"2521_CR2","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/sj.bjc.6605066","volume":"100","author":"D Mahalingam","year":"2009","unstructured":"Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ (2009) Targeting HSP90 for cancer therapy. Br J Cancer 100:1523\u20131529","journal-title":"Br J Cancer"},{"key":"2521_CR3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/cb600224w","volume":"1","author":"G Chiosis","year":"2006","unstructured":"Chiosis G, Neckers L (2006) Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol 1:279\u2013284","journal-title":"ACS Chem Biol"},{"key":"2521_CR4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","volume":"18","author":"L Neckers","year":"2012","unstructured":"Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18:64\u201376","journal-title":"Clin Cancer Res"},{"key":"2521_CR5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1042\/BJ20071640","volume":"410","author":"LH Pearl","year":"2008","unstructured":"Pearl LH, Prodromou C, Workman P (2008) The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 410:439\u2013453","journal-title":"Biochem J"},{"key":"2521_CR6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.5483\/BMBRep.2009.42.10.623","volume":"42","author":"JS Hahn","year":"2009","unstructured":"Hahn JS (2009) The Hsp90 chaperone machinery: from structure to drug development. BMB Rep 42:623\u2013630","journal-title":"BMB Rep"},{"key":"2521_CR7","first-page":"1483","volume":"23","author":"H Hao","year":"2010","unstructured":"Hao H, Naomoto Y, Bao X, Watanabe N, Sakurama K, Noma K, Motoki T, Tomono Y, Fukazawa T, Shirakawa Y, Yamatsuji T, Matsuoka J, Takaoka M (2010) HSP90 and its inhibitors. Oncol Rep 23:1483\u20131492","journal-title":"Oncol Rep"},{"key":"2521_CR8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","volume":"10","author":"J Trepel","year":"2010","unstructured":"Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537\u2013549","journal-title":"Nat Rev Cancer"},{"key":"2521_CR9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/jm701018h","volume":"51","author":"PA Brough","year":"2008","unstructured":"Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews TP, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, Workman P, Wright L (2008) 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51:196\u2013218","journal-title":"J Med Chem"},{"key":"2521_CR10","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1158\/0008-5472.CAN-07-5256","volume":"68","author":"SA Eccles","year":"2008","unstructured":"Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven BA, Gowan S, Boxall F, Aherne W, Rowlands M, Hayes A, Martins V, Urban F, Boxall K, Prodromou C, Pearl L, James K, Matthews TP, Cheung KM, Kalusa A, Jones K, McDonald E, Barril X, Brough PA, Cansfield JE, Dymock B, Drysdale MJ, Finch H, Howes R, Hubbard RE, Surgenor A, Webb P, Wood M, Wright L, Workman P (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68:2850\u20132860","journal-title":"Cancer Res"},{"key":"2521_CR11","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/bcr1996","volume":"10","author":"MR Jensen","year":"2008","unstructured":"Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, Garcia-Echeverria C, Chene P (2008) NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 10:R33","journal-title":"Breast Cancer Res"},{"key":"2521_CR12","unstructured":"Jensen M, Ide S, Brueggen J, Schoepfer J, Wang X, Quadt C, Garcia-Echeverria C (2009) Pharmacokinetic\/pharmacodynamic relationship of the HSP90 inhibitor NVP-AUY922 in human xenografts and patients in a clinical Phase I trial. Proc Am Assoc Cancer Res, 2009: 5649 [abstract]"},{"key":"2521_CR13","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/1535-7163.MCT-09-0683","volume":"9","author":"N Gaspar","year":"2010","unstructured":"Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, Pearson A, Vassal G, Workman P (2010) Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 9:1219\u20131233","journal-title":"Mol Cancer Ther"},{"key":"2521_CR14","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1158\/1078-0432.CCR-12-3404","volume":"19","author":"C Sessa","year":"2013","unstructured":"Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita MM, Papadimitrakopoulou V, Pluard T, Samuel TA, Akimov M, Quadt C, Fernandez-Ibarra C, Lu H, Bailey S, Chica S, Banerji U (2013) First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res 19:3671\u20133680","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"2521_CR15","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1200\/jco.2012.30.15_suppl.7543","volume":"30","author":"EB Garon","year":"2012","unstructured":"Garon EB, Moran T, Barlesi F, Gandhi L, Sequist LV, Kim S, Groen HJM, Besse B, Smit EF, Kim D, Akimov M, Avsar E, Bailey S, Felip E (2012) Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). J Clin Oncol 30(Suppl):7543","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"2521_CR16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1200\/jco.2012.30.15_suppl.530","volume":"30","author":"A Kong","year":"2012","unstructured":"Kong A, Rea D, Ahmed S, Beck JT, Lopez R, Biganzoli L, Armstrong A, Aglietta M, Alba E, Campone M, Akimov M, Matano A, Lefebvre C, Lee S (2012) Phase IB\/II study of the HSP90 inhibitor AUY922 in combination with trastuzumab, in patients with HER2\u00a0+\u00a0advanced breast cancer. J Clin Oncol 30(Suppl):530","journal-title":"J Clin Oncol"},{"key":"2521_CR17","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/sim.3230","volume":"27","author":"B Neuenschwander","year":"2008","unstructured":"Neuenschwander B, Branson M, Gsponer T (2008) Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 27:2420\u20132439","journal-title":"Stat Med"},{"key":"2521_CR18","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9","volume":"17","author":"J Babb","year":"1998","unstructured":"Babb J, Rogatko A, Zacks S (1998) Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 17:1103\u20131120","journal-title":"Stat Med"},{"key":"2521_CR19","first-page":"193","volume":"13","author":"Z Gao","year":"2010","unstructured":"Gao Z, Garcia-Echeverria C, Jensen MR (2010) Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. Curr Opin Drug Discov Devel 13:193\u2013202","journal-title":"Curr Opin Drug Discov Devel"},{"key":"2521_CR20","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.bbamcr.2011.10.008","volume":"1823","author":"K Jhaveri","year":"2012","unstructured":"Jhaveri K, Taldone T, Modi S, Chiosis G (2012) Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823:742\u2013755","journal-title":"Biochim Biophys Acta"},{"key":"2521_CR21","unstructured":"Demetri GD, Le Cesne A, Von Mehren M, Chmielowski B, Bauer S, Chow WA, Rodenas E, McKee K, Grayzel DS, Kang Y (2010) Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. In: ASCO Gastrointestinal Cancers Symposium 2010;64 [abstract]"},{"key":"2521_CR22","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.2005.12.085","volume":"23","author":"JL Grem","year":"2005","unstructured":"Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23:1885\u20131893","journal-title":"J Clin Oncol"},{"key":"2521_CR23","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-10-1927","volume":"17","author":"S Pacey","year":"2011","unstructured":"Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I (2011) A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 17:1561\u20131570","journal-title":"Clin Cancer Res"},{"issue":"Suppl 15s","key":"2521_CR24","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/jco.2010.28.15_suppl.3069","volume":"28","author":"G Shapiro","year":"2010","unstructured":"Shapiro G, Kwak EL, Dezube BJ, Lawrence DP, Cleary JM, Lewis S, Squires M, Lock V, Lyons JF, Yule M (2010) Phase I pharmacokinetic and pharmacodynamic study of the heat shock protein 90 inhibitor AT13387 in patients with refractory solid tumors. J Clin Oncol 28(Suppl 15s):3069","journal-title":"J Clin Oncol"},{"key":"2521_CR25","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1158\/1078-0432.CCR-11-0821","volume":"17","author":"A Rajan","year":"2011","unstructured":"Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannargudi B, Figg WD, Houk BE, Shnaidman M, Brega N, Giaccone G (2011) A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas. Clin Cancer Res 17:6831\u20136839","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"2521_CR26","doi-asserted-by":"crossref","first-page":"C212","DOI":"10.1158\/1535-7163.TARG-11-C212","volume":"10","author":"D Zhou","year":"2011","unstructured":"Zhou D (2011) A critical role for the tissue distribution profile in heat shock protein (Hsp) 90 inhibitor-induced ocular toxicity in rats. Mol Cancer Ther 10(Suppl 1):C212","journal-title":"Mol Cancer Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2521-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2521-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2521-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T14:46:11Z","timestamp":1598107571000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2521-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,25]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["2521"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2521-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,25]]}}}